ATE236650T1 - Verfahren zur hemmung der phagozytose - Google Patents

Verfahren zur hemmung der phagozytose

Info

Publication number
ATE236650T1
ATE236650T1 AT94929970T AT94929970T ATE236650T1 AT E236650 T1 ATE236650 T1 AT E236650T1 AT 94929970 T AT94929970 T AT 94929970T AT 94929970 T AT94929970 T AT 94929970T AT E236650 T1 ATE236650 T1 AT E236650T1
Authority
AT
Austria
Prior art keywords
methods
modulating
relates
receptors
antibody
Prior art date
Application number
AT94929970T
Other languages
English (en)
Inventor
Alan D Schreiber
Jong-Gu Park
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE236650T1 publication Critical patent/ATE236650T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94929970T 1993-09-30 1994-09-30 Verfahren zur hemmung der phagozytose ATE236650T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12938193A 1993-09-30 1993-09-30
PCT/US1994/011108 WO1995009002A1 (en) 1993-09-30 1994-09-30 Methods of inhibiting phagocytosis

Publications (1)

Publication Number Publication Date
ATE236650T1 true ATE236650T1 (de) 2003-04-15

Family

ID=22439683

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929970T ATE236650T1 (de) 1993-09-30 1994-09-30 Verfahren zur hemmung der phagozytose

Country Status (8)

Country Link
EP (1) EP0723455B1 (de)
JP (2) JPH09506072A (de)
AT (1) ATE236650T1 (de)
AU (1) AU701919B2 (de)
CA (1) CA2172392C (de)
DE (1) DE69432472D1 (de)
IL (1) IL111105A (de)
WO (1) WO1995009002A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
GB9510718D0 (en) * 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
JPH11507824A (ja) * 1995-06-07 1999-07-13 ユニバーシティー・オブ・ペンシルバニア 食作用を阻害する方法
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
KR20010041010A (ko) * 1998-02-17 2001-05-15 메다렉스, 인코포레이티드 Ｆｃ 수용체 리간드를 사용하여 마크로파지 매개 질환을치료하고 진단하는 방법
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
EP1006183A1 (de) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante, lösliche Fc-Rezeptoren
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7087585B2 (en) 2000-11-22 2006-08-08 The Trustees Of The University Of Pennsylvania Tripeptide of FcγRIIA
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
FR2702481B1 (fr) * 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique.

Also Published As

Publication number Publication date
EP0723455A1 (de) 1996-07-31
IL111105A (en) 2009-05-04
JPH09506072A (ja) 1997-06-17
WO1995009002A1 (en) 1995-04-06
JP2006217922A (ja) 2006-08-24
DE69432472D1 (de) 2003-05-15
AU701919B2 (en) 1999-02-11
IL111105A0 (en) 1994-11-28
CA2172392A1 (en) 1995-04-06
CA2172392C (en) 2011-06-21
EP0723455A4 (de) 1999-09-01
AU7924494A (en) 1995-04-18
EP0723455B1 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
DE69432472D1 (de) Verfahren zur hemmung der phagozytose
ES515177A0 (es) Procedimiento para el tratamiento de inmunoglobulina de suero.
ATE415172T1 (de) Behinderung der unterdrückung von t lymphozyten im zusammenhang mit der ctla-4 signalübertragung
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
ATE137802T1 (de) Monoklonaler antikörper, der mit einer neuen hla- determinante auf mhc-klasse-i-moleküle reagiert, und verfahren zur aktivierung von lymphozyten
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
DE69228556D1 (de) CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
DE68905610D1 (de) Verfahren zur herstellung von reflexionshologrammen in photopolymerisierbaren schichten.
EA200200503A1 (ru) Способ лечения ревматоидного артрита
ATE152170T1 (de) Verfahren zur aktivierung der zytolytischen wirkung von lymphozyten unter verwendung von anti-cd28-antikörper
ES2131527T3 (es) Anticuerpos monoclonales contra c-kit.
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
DE69312077D1 (de) Behandlung von autoimmun- und entzundungskrankheiten
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
DE69329344D1 (de) Spezifische modulationen des immunsystems
ATE161582T1 (de) Monoklonale antikörper der maus
EA199900409A1 (ru) Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний
ZA947783B (en) Method of treating depressed reticuloendothelial system function
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE219099T1 (de) Verfahren zur identifizierung von verbindungen, die zur behandlung von autoimmunkrankheiten verwendbar sind
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties